Slover Peter T 4

What Happened Peter T. Slover, Chief Financial Officer of Contineum Therapeutics, was granted a derivative award covering 192,000 shares (reported price $0.00) on 2026-01-30. The filing reports this as an award/acquisition (transaction code A); the reported dollar amount for the grant is $0.00 on the Form 4, indicating an option/award rather than a cash purchase of common stock.

Key Details

• Transaction date: 2026-01-30; transaction type: Award/Grant (code A).
• Reported amount: 192,000 shares; reported price per share: $0.00 (derivative award).
• Vesting: Options vest in equal monthly installments over 48 months, subject to continued service (per footnote).
• Filing timeliness: Reported and filed on 2026-01-30 (no late filing indicated in provided data).
• Post-transaction beneficial ownership: Not specified in the provided excerpt.

Context This was an option award (derivative grant) intended as equity compensation under the Issuer's 2024 Equity Incentive Plan; the award vests monthly over four years, meaning the shares are not immediately transferable. Such grants are common as retention/incentive compensation and are different from open-market purchases or insider sales.